Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign World Health Organization grade I neurofibroma

American Journal of Pathology

Volumn 168, Issue 5, 2006, Pages 1686-1696

  Wu, Jianqiang ^a   Crimmins, Jason T ^a   Monk, Kelly R ^a   Williams, Jon P ^a   Fitzgerald, Maureen E ^b   Tedesco, Susan ^b   Ratner, Nancy ^a,c  

^a Pediatric Critical Care Cincinnati Children's Hospital Medical Center   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; HISTOLOGY; HOT PLATE TEST; IMMUNOFLUORESCENCE; MAST CELL; MOUSE; NEUROFIBROMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PERINATAL PERIOD; PERIPHERAL NERVE TUMOR; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SAPHENOUS NERVE; SENSORY SYSTEM EXAMINATION; TRANSGENIC MOUSE; TREATMENT OUTCOME;

EID: 33646522740     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.050859     Document Type: Article

References (53)

1. Blatt J, Jaffe R, Deutsch M, Adkins J: Neurofibromatosis and childhood tumors. Cancer 1986, 57:1225-1229
2. Friedman J: Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999, 89:1-6
3. Huson S: Neurofibromatosis type 1: historical perspective and introductory overview. Neurofibromatosis Type 1: From Genotype to Phenotype. Edited by Upadhyaya M, Cooper DN (eds). Oxford, BIOS Science Publishers Ltd., 1998, pp 1-13
4. Huson S: The Neurofibromatosis. London, Chapman and Hall, 1994
5. Creange A, Zeller J, Rostaing-Rigattieri S, Brugieres P, Degos J, Revuz J, Wolkenstein P: Neurological complications of neurofibromatosis type 1 in adulthood. Brain 1999, 122:473-481
6. Korf B: Plexiform neurofibromas. Am J Med Genet 1999, 89:31-37
7. Wise J, Patel S, Ahah J: Management issues in massive pediatric facial plexiform neurofibroma with neurofibromatosis type 1. Head Neck 2002, 24:207-211
8. Needle M, Cnaan A, Dattilo J, Chatten J, Phillips P, Shochat S, Sutton L, Vaughan S, Zackai E, Zhao H, Molloy P: Prognostic signs in the surgical management of plexiform neurofibroma: the Children's Hospital of Philadelphia experience, 1974-1994. J Pediatr 1997, 131:678-682
9. Packer R, Gutmann D, Rubenstein A, Viskochil D, Zimmerman R, Vezina G, Small J, Korf B: Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology 2002, 58:1461-1470
10. Salomon D, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232
11. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61:203-212
12. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225
13. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogens 2000, 19:6550-6565
14. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7:2958-2970
15. Hirao T, Sawada H, Koyama F, Watanabe A, Yamada Y, Sakaguchi T, Tatsumi M, Fujimoto H, Emoto K, Narikiyo M, Oridate N, Nakano H: Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancer. Cancer Gene Ther 1999, 6:423-427
16. Ma L, Gauville C, Berthois Y, Millot G, Johnson G, Calvo F: Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line. Oncogene 1999, 18:6513-6520
17. Discafani C, Carroll M, Floyd MJ, Hollander I, Husain Z, Johnson B, Kitchen D, May M, Malo M, Minnick AJ, Nilakantan R, Shen R, Wang Y, Wissner A, Greenberger L: Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6- quinazolinyl]-2-butynamide (CL-387,785). Biochem Pharmacol 1999, 57:917-925
18. Nutt J, Lazarowicz H, Mellon J, Lunec J: Gefitinib ("Iressa," ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer 2004, 90:1679-1685
19. Yang X, Jia X, Corvalan J, Wang P, Davis C, Jakobovits A: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999, 59:1236-1243
20. Baselga J, Pfister D, Cooper M, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000, 18:904-914
21. Kawamoto T, Sato J, Le A, Polikoff J, Sato G, Mendelsohn J: Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 1983, 80:1337-1341
22. Fan Z, Masui H, Altas I, Mendelsohn J: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993, 53:4322-4328
23. Goldstein N, Prewett M, Zuklys K, Rockwell P, Mendelsohn J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995, 1:1311-1318
24. Karashima T, Sweeney P, Slaton J, Kim S, Kedar D, Izawa J, Fan Z, Pettaway C, Hicklin D, Shuin T, Dinney C: Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002, 8:1253-1264
25. Sclabas G, Fujioka S, Schmidt C, Fan Z, Evans D, Chiao P: Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J Gastrointest Surg 2003, 7:37-43
26. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345
27. Serra E, Puig S, Otero D, Gaona A, Kruyer H, Ars E, Estivill X, Lazaro C: Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am J Hum Genet 1997, 61:512-519
28. DeClue JE, Heffelfinger S, Benvenuto G, Ling B, Li S, Rui W, Vass WC, Viskochil D, Ratner N: Epidermal growth factor receptor expression in neurofibromatosis type-1 related tumors and NF1 animal models. J Clin Invest 2000, 105:1-10
29. Stonecypher M, Byer S, Grizzle W, Carroll S: Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors. Oncogene 2005, 24:5589-5605
30. Li H, Velasco-Miguel S, Vass W, Parada L, DeClue J: Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res 2002, 62:4507-4513
31. Ling B, Wu J, Miller S, Monk K, Shamekh R, Rizvi T, Decourten-Myers G, Vogel K, DeClue J, Ratner N: Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 2005, 7:65-75
32. Brannan C, Perkins A, Vogel K, Ratner N, Nordlund M, Reid S, Buchberg A, Jenkins N, Parada L, Copeland N: Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994, 8:1019-1029
33. Plone M, Emerich D, Lindner M: Individual differences in the hotplate test and effects of habituation on sensitivity to morphine. Pain 1996, 66:265-270
34. Chen S, Rio C, Ji R, Dikkes P, Coggeshall R, Woolf C, Corfas G: Disruption of ErbB receptor signaling in adult non-myelinating Schwann cells causes progressive sensory loss. Nat Neurosci 2003, 6:1186-1193
35. Miller SJ, Li H, Rizvi TA, Huang Y, Johansson G, Bowersock J, Sidani A, Vitullo J, Vogel K, Parysek LM, DeClue JE, Ratner N: Brain lipid binding protein in axon-Schwann cell interactions and peripheral nerve tumorigenesis. Mol Cell Biol 2003, 23:2213-2224
36. Roberts R, Min L, Washington M, Olsen S, Settle S, Coffey R, Threadgill D: Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 2002, 99:1521-1526
37. Grinspan J, Marchionni M, Reeves M, Coulaloglou M, Scherer S: Axonal interactions regulate Schwann cell apoptosis in developing peripheral nerve: neuregulin receptors and the role of neuregulins. J Neurosci 1996, 16:6107-6118
38. Carr N, Warren A: Mast cell numbers in melanocytic naevi and cutaneous neurofibromas. J Clin Pathol 1993, 46:86-87
39. Zhang Y, Vik T, Ryder J, Srour E, Jacks T, Shannon K, Clapp D: Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med 1998, 187:1893-1902
40. Demitsu T, Kiyosawa T, Kakurai M, Murata S, Yaoita H: Local injection of recombinant human stem cell factor promotes human skin mast cell survival and neurofibroma cell proliferation in the transplanted neurofibroma in nude mice. Arch Dermatol Res 1999, 291:318-324
41. Mashour G, Ratner N, Khan G, Wang H, Martuza R, Kurtz A: The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 2001, 20:97-105
42. Kotsuji-Maruyama T, Imakado S, Kawachi Y, Otsuka F: PDGF-BB induces MAP kinase phosphorylation and VEGF expression in neurofibroma-derived cultured cells from patients with neurofibromatosis 1. J Dermatol 2002, 29:713-717
43. Krasnoselsky A, Massay M, DeFrances M, Michalopoulos G, Zarnegar R, Ratner N: Hepatocyte growth factor is a mitogen for Schwann cells and is present in neurofibromas. J Neurosci 1994, 14:7284-7290
44. Kadono T, Soma Y, Takehara K, Nakagawa H, Ishibashi Y, Kikuchi K: The growth regulation of neurofibroma cells in neurofibromatosis type-1: increased responses to PDGF-BB and TGF-beta 1. Biochem Biophys Res Commun 1994, 198:827-834
45. Kawachi Y, Xu X, Ichikawa E, Imakado S, Otsuka F: Expression of angiogenic factors in neurofibromas. Exp Dermatol 2003, 12:412-417
46. Mashour G, Wang H, Cabal-Manzano R, Wellstein A, Martuza R, Kurtz A: Aberrant cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type-1. J Invest Dermatol 1999, 113:398-402
47. Kitano Y, Okamoto E, Saito K, Okano Y: Effects of several growth factors on cultured neurofibroma cells. J Dermatol Sci 1992, 3:137-144
48. Perry A, Kunz S, Fuller C, Banerjee R, Marley E, Liapis H, Watson M, Gutmann DH: Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol 2002, 61:702-709
49. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, Jacks T: Mouse models of tumor development in neurofibromatosis type 1. Science 1999, 286:2172-2176
50. Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF: Mouse tumor model for neurofibromatosis type 1. Science 1999, 286:2176-2179
51. Zhu Y, Ghosh P, Charnay P, Burns D, Parada L: Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002, 296:920-922
52. Morris J, Lin W, Hauser C, Marchuk Y, Getman D, Lee K: Rescue of the cardiac defect in ErbB2 mutant mice reveals essential roles of ErbB2 in peripheral nervous system development. Neuron 1999, 23:273-283
53. Miettinen P: Epidermal growth factor receptor in mice and men-any applications to clinical practice? Ann Med 1997, 29:531-534